Author | Age | Involved eye: Duration to CRVO | Associated Systemic Abnormality | Treatment | Complications | Final BCVA |
---|---|---|---|---|---|---|
Foss et al. 1992 [13] | 23/M | LE: 4wks | None | Systemic CS, PRP | NVG | LP |
54/M | RE: simultaneous | None | PRP | CME | CF | |
Seo et al. 1998 [14] | 27/M | LE: 4 months | None | Systemic CS, PRP | NVG, VH | HM |
Kaburaki et al 2001 [15] | 36/F | RE: 3wks | None | Systemic CS, PRP | NVG, VH | LP |
23/F | LE: 2wks | High RF | Systemic CS, PRP | NVG | LP | |
Abu El-Asrar et al. 2003 [16] | 28/M | RE: 2wks LE: -10 days | Carotid artery stenosis Antiphospholipid antibodies | Systemic CS, azathioprine, Plasmapheresis, PRP | OD: phthisis bulbi OS: TRD OU: NVG | NLP OU |
47/M | LE: simultaneous | Antiphospholipid antibodies High Homocysteine | Systemic CS, PRP | Rubeosis irides | N/A | |
Satoh et al 2010 [17] | 39/M | LE: -4 days | Familial Mediterranean Fever | Systemic CS, Antiviral, Antibacterial | N/A | 20/20 |
Greifner et al 2016 [18] | 37/M | LE: 3 months | None | Systemic CS, Anti-VEGF | CME | 20/30 |
45/F | RE: 4 months | None | Systemic CS, Anti-VEGF | CME | 20/50 | |
Kumawat et al. 2017 [19] | 28/M | LE: -3 days | None | Systemic CS | CME | 20/20 |